| Literature DB >> 26238782 |
Paul William Harms1,2,3, Pankaj Vats1,4, Monique Elise Verhaegen3, Dan R Robinson1, Yi-Mi Wu1,2, Saravana Mohan Dhanasekaran1, Nallasivam Palanisamy1,2,5, Javed Siddiqui1,2, Xuhong Cao1,6, Fengyun Su1, Rui Wang1,2, Hong Xiao1,2,5, Lakshmi P Kunju1,2, Rohit Mehra1,2,5, Scott A Tomlins1,2,7,8, Douglas Randall Fullen2,3, Christopher Keram Bichakjian3, Timothy M Johnson3, Andrzej Antoni Dlugosz3,9, Arul M Chinnaiyan1,2,6,7,8.
Abstract
Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous neuroendocrine tumor. Merkel cell polyomavirus (MCPyV) may contribute to tumorigenesis in a subset of tumors via inhibition of tumor suppressors such as retinoblastoma (RB1) by mutated viral T antigens, but the molecular pathogenesis of MCPyV-negative MCC is largely unexplored. Through our MI-ONCOSEQ precision oncology study, we performed integrative sequencing on two cases of MCPyV-negative MCC, as well as a validation cohort of 14 additional MCC cases (n = 16). In addition to previously identified mutations in TP53, RB1, and PIK3CA, we discovered activating mutations of oncogenes, including HRAS and loss-of-function mutations in PRUNE2 and NOTCH family genes in MCPyV-negative MCC. MCPyV-negative tumors also displayed high overall mutation burden (10.09 ± 2.32 mutations/Mb) and were characterized by a prominent UV-signature pattern with C > T transitions comprising 85% of mutations. In contrast, mutation burden was low in MCPyV-positive tumors (0.40 ± 0.09 mutations/Mb) and lacked a UV signature. These findings suggest a potential ontologic dichotomy in MCC, characterized by either viral-dependent or UV-dependent tumorigenic pathways. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26238782 PMCID: PMC4573907 DOI: 10.1158/0008-5472.CAN-15-0702
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701